Clodronate (Bonefos)
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity, dissolution of hydroxyapatite crystals, and bone resorption/turnover.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Disease-specific information
For now this will be a gathering point for RCTs examining the use of this agent, which does not have clear antineoplastic properties; in the future this information may be moved to separate page(s).
Multiple myeloma
- MRC Myeloma IX: Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010 Dec 11;376(9757):1989-99. Epub 2010 Dec 3. link to original article link to PMC article PubMed
Patient drug information
History of changes in FDA indication
Not FDA approved; used in several other countries (Canada, Australia, the United Kingdom, Italy, others).
Also known as
- Generic names: clodronate disodium, clodronic acid disodium tetrahydrate
- Brand names: Clasteon, Clastoban, Climaclod, Clodeosten, Clodran, Clodron, Clody, Difosfonal, Disdual, Lodronat, Loron, Lytos, Mebonat, Moticlod, Niklod, Ossiten, Ostac, Osteonorm, Osteostab, Sindronat